H. Jack West, Vice President of Clinical Development at Summit Therapeutics, Inc., shared a post on X:
“People rightfully debate the importance of PFS vs. OS in general, but I would contend that PFS endpoint is definitely aiming low when local therapy is used for OMD — you are eradicating most expected site of PD.
I’ve become a believer in local Rx for OMD overall, but non-rad oncs are going to be rightfully skeptical until OMD studies aim higher than the ‘layup’ of showing PFS benefit from local Rx.”
Nina Niu Sanford, Assistant Professor and Chief of Gastrointestinal Radiation Oncology at Harvard/Brigham and Women’s Hospital/Massachusetts General Hospital, shared H. Jack West’s post on X, adding:
“Appreciate Jack’s perspective.
B/c SBRT usually low toxicity and convenient, we see how PFS translates into meaningful benefits – time off systemic, less treatment burden.
But agree trials should directly test improvements in pt-centered endpoints vs relying on radiographic PFS surrogate.”
The discussion evolved around a post by David Palma, Radiation Oncologist at London Health Sciences Centre (LHSC):
“Here are all the oligomets RCTs.
HRs < 1 in green.”
More posts featuring H. Jack West.